Abstract
To determine the impact of neutropenia on the pharmacokinetics of meropenem, 14 patients with fever and neutropenia were given 1 g of meropenem i.v. every 8 h as an infusion over 30 min. The volume of distribution (16.2 1/1.73 m2) and the nonrenal clearance [75 ml/(min x 1.73 m2)] in this group were significantly increased compared to healthy subjects studied previously with identical techniques. The kinetic study was repeated when the patients had a normal temperature and a raised neutrophil count; most kinetic variables did not differ from the findings on the first day of treatment. The pharmacokinetic profile of meropenem in febrile neutropenic patients differs from earlier findings in healthy subjects. Considering these data and known minimum inhibitory concentration values for common pathogens, meropenem administered every 6 to 8 h seems an appropriate regimen in patients with febrile neutropenia. The shorter time interval may be used for treatment ofPseudomonas infection.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, Bucaneve G, Crokaert F, Kern WV, Klastersky J, Langenaeken J, Micozzi A, Padmos A, Paesmans M, Viscoli C, Glauser MP, the International Antimicrobial Therapy Cooperative Group of the European Organisation for Research and Treatment of Cancer and the Gruppo Italiano Malettie Ematologiche Maligne Dell'Adulto Infection Program: Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrobial Agents and Chemotherapy 1996, 40: 1108–1115.
De Pauw BE, Boogaerts MA, Demuynck H, Mestdagh N, Verbist L, Goldstone AH, Kelsey HC, Machin S, Donelly JP, Raemaekers JMM, Atkinson G, Williams KJ: Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. Journal of Antimicrobial Chemotherapy 1995, 36: 185–200.
Ljungberg B, Nilsson-Ehle I: Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acute ill males. European Journal of Clinical Pharmacology 1988, 34: 179–186.
Ljungberg B, Nilsson-Ehle I: Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men. Antimicrobial Agents and Chemotherapy 1992, 36: 1437–1440.
Bäck SE, Ljungberg B, Nilsson-Ehle I, Borgå O, Nilsson-Ehle P: Age dependence of renal function: clearance of iohexol and p-amino hippurate in healthy males. Scandinavian Journal of Clinical Laboratory Investigation 1989, 49: 641–646.
Granerus G, Aurell M: Reference values for51Cr-EDTA as a measure of GFR. Scandinavian Journal of Clinical Laboratory Investigation 1981, 41: 611–616.
Krutzén E, Bäck SE, Nilsson-Ehle I, Nilsson-Ehle P: Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate. Journal of Laboratory and Clinical Medicine 1984, 104: 955–961.
Nilsson-Ehle I, Hutchinson M, Haworth SJ, Norrby SR: Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. European Journal of Clinical Microbiology & Infectious Diseases 1991, 10: 85–88.
Gibaldi M: Biopharmaceutics and clinical pharmacokinetics. Lea & Febiger, Philadelphia, 1991, p. 14–23.
Schentag JJ: Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values and bacterial eradication in patients with gram-negative pneumonia. Scandinavian Journal of Infectious Diseases 1991, Supplement 74: 218–234.
Vogelman B, Gudmundsson S, Legget J, Turnidge J, Ebert S, Craig WA: Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. Journal of Infectious Diseases 1988, 158: 831–847.
Drusano GL: Role of pharmacokinetics in the outcome of infections. Minireview. Antimicrobial Agents and Chemotherapy 1988, 32: 289–297.
Bodey GP, Ketchel SJ, Rodriguez V: A randomized study of carbenicillin plus cefamandole ortobramycin in the treatment of febrile episodes in cancer patients. American Journal of Medicine 1979, 67: 608–616.
Nadler HL, Pitkin DH, Sheikh W; The postantibiotic effect of meropenem and imipenem on selected bacteria. Journal of Antimicrobial Chemotherapy 1989, 24, Supplement A: 225–231.
Hanberger H, Svensson E, Nilsson LE, Nilsson M: Pharmacodynamic effects of meropenem on gram-negative bacteria. European Journal of Clinical Microbiology & Infectious Diseases 1995, 14: 383–390.
Fuentes F, Martin MM, Izquierdo J, Gomez-Lus ML, Prieto J: In vivo and in vitro study of several pharmacodynamic effects of meropenem. Scandinavian Journal of Infectious Diseases 1992, 27: 469–474.
Odenholt-Tornqvist I: Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem. Journal of Antimicrobial Chemotherapy 1993, 31: 881–892.
Wu PJ, Livermore DM: Response of chemostat cultures ofPseudomonas aeruginosa to carbapenems and other β-lactams. Journal of Antimicrobial Chemotherapy 1990, 25: 891–902.
Craig WA: Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. European Journal of Clinical Microbiology & Infectious Diseases 1993, 12: 6–8.
Daenen S, Erjavec Z, Uges DRA, De Vries-Hospers HG, De Jonge R Halie MR: Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. European Journal of Clinical Microbiology & Infectious Diseases 1995, 14: 188–192.
Craig WA, Ebert SC: Continuous infusion of β-lactam antibiotics. Minireview. Antimicrobial Agents and Chemotherapy 1992, 36: 2577–2583.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nyhlén, A., Ljungberg, B., Nilsson-Ehle, I. et al. Pharmacokinetics of meropenem in febrile neutropenic patients. Eur. J. Clin. Microbiol. Infect. Dis. 16, 797–802 (1997). https://doi.org/10.1007/BF01700408
Issue Date:
DOI: https://doi.org/10.1007/BF01700408